Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Newer

SeriousMoney

10/26/05 12:51 PM

Post #5

Re: #4: @SeriousMoney - Amylin May See Q3 Upside On Strong Byetta

Amylin Pharmaceuticals, Inc. Earnings Conference Call (Q3 2005)
Scheduled to start Wed, Oct 26, 2005, 5:00 pm Eastern

http://biz.yahoo.com/cc/6/61876.html

SeriousMoney

10/26/05 12:46 PM

Post #4

Re: #2: @SeriousMoney - Amylin Pharmaceuticals Slide Presentation for UBS Global Life

Amylin May See Q3 Upside On Strong Byetta Sales
<Peter Kang, Forbes.com, 10.25.05>

Piper Jaffray maintained an "outperform" rating on Amylin Pharmaceuticals (nasdaq: AMLN - news - people ) ahead of the biotechnology company's release of third-quarter results on Wednesday.

"We continue to believe that Byetta will exceed Street expectations and upside to estimates could result in a second leg of stock appreciation near term," wrote analyst Thomas Wei in a note to investors.

http://www.forbes.com/markets/2005/10/25/amylin-pharmaceuticals-earnings-1025markets14.html?partner=...

SeriousMoney

10/20/05 2:23 AM

Post #2

Re: #1: @SeriousMoney - Amylin Pharmaceuticals to Present at UBS Global Life

Amylin Pharmaceuticals Slide Presentation for UBS Global Life Sciences Conference on 10/27/05

http://library.corporate-ir.net/library/10/101/101911/items/167886/UBS_FINAL100505.pdf

SeriousMoney

10/20/05 2:20 AM

Post #1

Amylin Pharmaceuticals to Present at UBS Global Life Sciences Conference

SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the UBS Global Life Sciences Conference on Tuesday, September 27, 2005 at 8:00 a.m. ET in New York. Daniel M. Bradbury, Chief Operating Officer of Amylin Pharmaceuticals, will be providing a corporate overview.

The live presentation and breakout session will be webcast, and recordings will be made available following the event. The webcasts and recordings will be accessible through Amylin's corporate website, located at www.amylin.com. To access the live webcasts, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.

SOURCE Amylin Pharmaceuticals, Inc. 09/22/2005
CONTACT: Alice Bahner, Executive Director, Investor Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 7272
Web site: http://www.amylin.com (AMLN)

http://investors.amylin.com/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=759717&highligh...

Newer

Amylin Pharmaceuticals Inc. (AMLN)

Followers	12	Posters	36
Posts (Today)	0	Posts (Total)	167
Created	10/20/05	Type	Free
Moderators

http://www.amylin.com

http://finance.yahoo.com/q/pr?s=AMLN

http://www.form4oracle.com/company?cik=0000881464&ticker=amln

Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States. It sells BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection for the treatment of patients with Type II diabetes. The company also has research and development programs in the therapeutic areas of diabetes and obesity, including exenatide once weekly; Nasal Exenatide, a nasal spray formulation of exenatide for diabetes; Pramlintide and PYY 3-36 for the treatment of obesity; Leptin for the treatment of obesity and lipodystrophy; Pramlintide-Metreleptin combination product candidate for overweight or obese subjects; and second generation Amylinomimetic for weight loss. It sells its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers, and other third-party payors. The company has collaboration agreements with Eli Lilly and Company, as well as with Alkermes, Inc. to develop exenatide once weekly for diabetes; a contract research arrangement with Kelaroo, Inc. for the commercialization of Kelaroo's SeqR technology that is used for peptide hormone identification and optimization; a joint research collaboration agreement with BioSeek, Inc. for discovery and development of novel peptide therapeutics for inflammatory conditions; and a joint research collaboration agreement with Xenome, Ltd. for discovery and development of novel peptide hormones for a range of metabolic and musculoskeletal diseases. It also has a collaboration with Pacira Pharmaceuticals, Inc. for the development of sustained release injectable products based on the DepoFoam technology platform. Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California.